Shareholders Approve New Equity Plan and Grant Right to Act by Written Consent

summarizeSummary

Vertex Pharmaceuticals shareholders approved a new 2026 Stock and Option Plan, authorizing a significant amount of shares for future compensation, alongside a corporate governance change allowing shareholders to act by written consent.

check_boxKey Events

• 2026 Stock and Option Plan Approved

  Shareholders approved the 2026 Stock and Option Plan, replacing the 2013 plan and authorizing a new pool of shares for future equity awards. This plan was previously disclosed as having over 6% potential dilution.

• Shareholder Right to Act by Written Consent Approved

  A shareholder proposal granting the right to act by written consent was approved, enhancing shareholder influence on corporate matters.

• Routine Annual Meeting Approvals

  Shareholders re-elected all directors, ratified Ernst & Young LLP as the independent auditor, and approved the 2025 executive compensation program on an advisory basis.

auto_awesomeAnalysis

Vertex Pharmaceuticals shareholders approved the 2026 Stock and Option Plan, which authorizes a substantial pool of shares for future employee compensation. While necessary for talent retention, this plan introduces significant potential dilution for existing shareholders, as previously outlined in the proxy statement. Additionally, shareholders approved a proposal granting them the right to act by written consent, enhancing corporate governance.